The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade ...

BioNTech to invest £1B in UK R&D over 10 years, receives £129M government grant to build research centers and HQ in London, ...

Mod­er­na pulls BLA for its Covid-flu shot: The com­pa­ny sug­gest­ed on its most re­cent … Get free access to a limited ...

PureTech's deupirfenidone outperforms Roche's Esbriet in lung fibrosis trial, showing greater lung function preservation with ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according ...

ReproNovo raises $65M for trials of leflutrozole and nolasiban in reproductive health. CEO Jean Marie Duvall plans Phase 2 ...

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

Senate Democrats grilled Kennedy on Tuesday over gaps in his budget and funding cuts that have halted or eliminated key ...

Duncan Reece shares why his dementia care startup Veronica Health closed before seeing patients, citing fundraising challenges and investor skepticism of value-based care.

Biotech execs express concerns over FDA changes, NIH cuts, and Trump's tariffs. Industry confidence low amid poor funding ...